卵巢癌微环境中肿瘤相关巨噬细胞与患者预后的相关性研究OA

Objective:Ovarian cancer is one of the deadliest malignancies among women worldwide,with the majority of patients diagnosed at advanced stages.High recurrence rates and chemotherapy resistance remain significant challenges in treatment.In recent years,the tumor microenvironment(TME)has gained attention for its role in drug resistance and metastasis in ovarian cancer,with tumor-associated macropha-ges(TAMs)as a crucial component of TME.TAMs may in-fluence the prognosis of ovarian cancer through immune modu-lation and pro-tumor mechanisms.This study aims to investigate the spatial distribution of TAM subsets(CD68+,CD163+,CD80+)in ovarian cancer tumor nests versus stroma and to evaluate their association with clinicopathological characteristics and patient prognosis,thereby offering potential implications for immunotherapy strategies.Methods:Patient samples diag-nosed with ovarian cancer were collected from the Second Affiliated Hospital of Zunyi Medical University between January 2007 and December 2017.We analyzed the clinicopathological characteristics of the patients and the expression of TAM markers(CD68,CD163,CD80)by immunohistochemistry.Subsequently,by combining the clinical follow-up data,we em-ployed Kaplan-Meier survival analysis and Cox proportional hazards regression models to explore the correlation between TAM expression and patient prognosis.Results:Among the 56 ovarian cancer patients,significant differences in the expression of CD68+,CD163+,and CD80+TAMs were observed in both the tumor nest and stroma.High expression of CD68+TAMs in the stroma was associated with worse progression-free survival(PFS)and overall survival(OS)(P=0.001,P=0.003).High expression of M2-type TAMs(CD163+)in the stroma was linked to poor prognosis in ovarian cancer patients,while high expression of M1-type TAMs(CD80+)and CD80+/CD68+TAMs in the stroma correlated with better PFS and OS(P=0.029).Additionally,high expression of CD163+/CD68+TAMs was associated with worse prognosis,suggesting that M2-type TAMs may promote tumor progression.Conclusion:This study reveals the spatial distribution and subtype-specific ex-pression of TAMs in ovarian cancer,indicating that high expression of CD68+and CD163+TAMs in both the tumor nest and stroma is associated with poor prognosis in ovarian cancer patients,especially the high expression of CD163+TAMs in the stroma.Conversely,CD80+TAMs were identified as a favorable prognostic marker.These findings provide new directions for ovarian cancer immunotherapy,suggesting that reshaping TAMs toward M1 polarization or inhibiting their M2 polarization could improve patient prognosis.